Bromfenac
- Generic Name
- Bromfenac
- Brand Names
- Bromday, Bromsite, Prolensa, Xibrom, Yellox
- Drug Type
- Small Molecule
- Chemical Formula
- C15H12BrNO3
- CAS Number
- 91714-94-2
- Unique Ingredient Identifier
- 864P0921DW
- Background
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes. Non-oph...
- Indication
For the treatment of postoperative inflammation in patients who have undergone cataract extraction.
- Associated Conditions
- Eye Pain, Ocular Inflammation
- Associated Therapies
- -
Effectiveness of Periocular Drug Injection in CATaract Surgery
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Luigi Rondas
- Target Recruit Count
- 628
- Registration Number
- NCT05158699
- Locations
- 🇳🇱
Amphia, Breda, Netherlands
🇦🇹Hospital of the Brothers of Saint John of God, Vienna, Austria
🇦🇹Vienna Institute for Research in Ocular Surgery, Hanusch Krankenhaus, Vienna, Austria
Control of Pain in Intravitreal Injections Using Topical NSAIDs
- Conditions
- Interventions
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 46
- Registration Number
- NCT04343222
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Silverstein Eye Centers
- Target Recruit Count
- 57
- Registration Number
- NCT03886779
PRevention of Macular EDema After Cataract Surgery
- Conditions
- Interventions
- First Posted Date
- 2013-01-24
- Last Posted Date
- 2017-04-14
- Lead Sponsor
- Maastricht University Medical Center
- Target Recruit Count
- 1127
- Registration Number
- NCT01774474
- Locations
- 🇦🇹
Hospital of the Brothers of Saint John of God, Vienna, Austria
🇧🇪University Hospital Antwerp, Edegem, Belgium
🇳🇱Academic Medical Center, Amsterdam, Netherlands
Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.
- First Posted Date
- 2012-02-17
- Last Posted Date
- 2019-10-16
- Lead Sponsor
- Laboratorios Sophia S.A de C.V.
- Target Recruit Count
- 35
- Registration Number
- NCT01535443
- Locations
- 🇲🇽
Unidad Medica "Grupo Pediátrico", Guadalajara, Jalisco, Mexico
Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2016-05-03
- Lead Sponsor
- Virdi Eye Clinic
- Target Recruit Count
- 20
- Registration Number
- NCT01475877
- Locations
- 🇺🇸
Virdi Eye Clinic and Laser Vision Center, Rock Island, Illinois, United States
Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%
- First Posted Date
- 2011-03-08
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- Toyos Clinic
- Target Recruit Count
- 23
- Registration Number
- NCT01310127
A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification
- Conditions
- Interventions
- First Posted Date
- 2009-11-30
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- Frank A. Bucci, Jr., M.D.
- Target Recruit Count
- 126
- Registration Number
- NCT01021761
Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2009-06-10
- Lead Sponsor
- Bp Consulting, Inc
- Target Recruit Count
- 25
- Registration Number
- NCT00828477
- Locations
- 🇺🇸
Coburn-Kleinfeldt Eye Clinic, 3340 6 mile Rd Livonia, Michigan, United States
Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
- Conditions
- Interventions
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2012-03-15
- Lead Sponsor
- Bp Consulting, Inc
- Target Recruit Count
- 49
- Registration Number
- NCT00758199
- Locations
- 🇺🇸
Altos Eye Physicians, Los Altos, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.